GOSS Company Profile and Key Details

GOSS has shown sold momentum, gaining 3.17% over the past week and 18.72% over the past quarter, though year-to-date performance is down -16.13%. Short-term trend indicators are mixed aligned (SMA20 -79.24%, SMA50 -84.14%, SMA200 -82.17%). The stock’s 14-day RSI is 14.83 (weak momentum), while the ATR of 0.27 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -89.61% below its high and over 21.38% above its low. Average 10-day trading volume of 23.94 million shares is in line with the 3-month average of 26.32 million, indicating normal recent market interest.

The stock is currently mid-range between its 52-week high and low $0.11 and $3.87. With a market capitalization of about $75.62 million, Gossamer Bio, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.01). Key stats such as the average daily volume over the past year has been around 25.10 million shares, trading with heavier-than-usual volume. Headquartered in San Diego, CA, Gossamer Bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Faheem Hasnain, the company employs approximately 162 people and listed since February 08, 2019. Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States.

Gossamer Bio, Inc. has 488.85 million shares outstanding. The public float is 147.46 million shares, elevated short interest at 15.18% of float. This equals 73.18 million shares. The short ratio is 4.03 days. Institutional investors hold 69.38% of the float. Insiders own 1.52%. Omega Fund V, L.P. holds 6.55 million shares, Hasnain Faheem has 5.41 million shares and Gujrathi Sheila has 4.05 million shares.

Gossamer Bio, Inc. generated EPS of -$0.69 over the past year. Five-year average earnings growth is 40.29%. Wall Street analysts project EPS growth of 13.11% annually over the next five years. The latest quarter delivered EPS of -$0.20. The next quarter is forecast at -$0.19. Next year's EPS is expected at $35.24. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 6 Buy ratings, 2 Hold ratings, 0 Sell rating and 2 Strong Sell ratings. Price targets range from $12.00 to $0.28. The high target offers 7900.0% upside. The low target suggests 86.67% downside. The mean target is $6.25. This offers 4066.67% upside. Gossamer Bio, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 13, 2026, missed forecasts by 62.04%. The prior quarter beat by 17.65%. Over the last six quarters, Apple has recorded several small beats. These include -5.56% in August 05, 2025.

Gossamer Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.10. This means the shares are trading above this model’s fair value.

Gossamer Bio, Inc. trades at a P/E ratio of -0.27, slightly below the S&P 500 average, with a price-to-sales ratio of 1.39 and a price-to-book ratio of -0.51 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.45, also below market averages.

Gossamer Bio, Inc. (NASDAQ:GOSS) shares are down -16.13% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Gossamer Bio, Inc. trading at a premium to the broader market with a P/E of -0.27. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $11.37, suggesting 7249.71% upside. Our AI forecast model points to short-term strength (3.43% over two weeks), a medium-term fall (-67.68% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Gossamer Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 3.43%, with price expected at $0.16 by September 03, 2026, within a range of $0.13 to $0.18 3-Month Outlook: Projected fall of -67.68%, reaching $0.05 by November 18, 2026, with a range of $0.00 to $0.11. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by August 20, 2027, within a range of $0.00 to $0.07.